Abdalla Aly, PhD

Senior Director, Real-World Evidence
Novo Nordisk Inc.

Poster(s):

• (184) Real-world healthcare resource utilization and costs among 100% Fee-For-Service Medicare beneficiaries with metabolic dysfunction-associated steatohepatitis
  Wednesday, October 29, 2025

• (389) Healthcare Resource Utilization and Costs in Patients with Metabolic Dysfunction Associated Steatohepatitis: A Comparison Between Patients with Diagnosed MASH, Probable MASH, and Without MASH
  Wednesday, October 29, 2025